Acumen Pharmaceuticals
Price & Volume
Stats
See more52W Range | $1.19-$3.60 |
Market Cap | $189.9M |
Shares Short | 2M |
Financials
See moreRevenue (12 Mos) | $329,000 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | -$104.9M |
Diluted EPS | -$1.85 |
News
See moreYahoo Finance • 7 days ago
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
Yahoo Finance • 28 days ago
Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease
Yahoo Finance • 28 days ago
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease
Yahoo Finance • 4 months ago
Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding
About
CEO | Mr. Daniel J. O'Connell M.B.A. |
CFO | Mr. Matt Zuga |
Address | 1210-1220 Washington St., Newton, MA, United States, 02465 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 60 |